Compared with HRG, LRG patients exhibited high drug sensitivity on tyrosine kinase inhibitor (axitinib) [63], polyadenosine diphosphate‐ribose polymerase‐1 inhibitors (AG.014699 and AZD.2281) [64, 65], Bcl‐2/xL inhibitor (ABT.263) [66], TANK‐binding protein‐1 inhibitor (BX.795) [67], and PP2Cδ inhibitor (CCT007093) [68], which may become potential druggable targets for ESCC patients. The gene discussed is BCL2; the disease is esophageal squamous cell carcinoma.